Schedule
Personalized Medicine Conference 2026 • November 18 –19
Hyatt Regency Boston/Cambridge • Cambridge, MA
We’re building an exceptional program for 2026.
Visit the website for the latest program updates as speakers are announced. Agenda timing subject to change.
Schedule
PART I
Personalized Medicine Reimagined: Emerging Technologies Transforming Research & Care
SPEAKER | Gina Ross Murdoch, MBA, President and CEO, Personalized Medicine Coalition
This session will explore how emerging AI technologies are transforming drug discovery and development through clinical care – from de novo drug design and target identification to clinical trial design and preventive care. Looking ahead to 2050, panelists will examine whether technologies such as AI, computational diagnostics, and digital health tools will accelerate R&D and expand access to personalized care or risk creating new digital and systemic barriers, particularly in resource-limited communities. The discussion will also focus on how companies are leveraging advances in AI today to foster discoveries of tomorrow.
While oncology has driven many of the earliest breakthroughs in precision medicine, rapid advances in genomics, biomarker science, AI, digital health, and molecular diagnostics are now transforming care across a wide range of diseases and conditions. From cardiovascular and neurodegenerative diseases to autoimmune disorders, rare disease, infectious disease, and metabolic conditions, precision medicine is reshaping how conditions are identified, monitored, prevented, and treated.
This panel will explore how emerging technologies and scientific discoveries are enabling more personalized approaches far beyond cancer care. Panelists will discuss these new areas of impact, where scientific and implementation barriers remain, and key learnings from the application of precision approaches across disease states.
As molecular diagnostics platforms generate increasingly large and complex datasets, AI is emerging as a powerful tool to support quality, interpretation, and clinical decision-making across disease areas, including immunology and rare disease. This panel discussion will explore how organizations across the personalized medicine ecosystem are using AI today to improve the analysis and usability of molecular and genomic data, while also addressing the validation, governance, and workflow considerations required for responsible implementation. This conversation will also focus on how AI can help translate complex diagnostic information into trusted, scalable insights that support better patient care and broader adoption of personalized medicine.
Following the 2026 mid-term elections, what will dominate the policy conversations related to personalized medicine? Panelists will discuss potential implications for areas critical to supporting personalized medicine research, adoption, coverage, and reimbursement.
Advances in blood-based diagnostic testing for cancer are transforming how other diseases can be identified, even years before symptoms emerge. Yet while the scientific promise of early detection has accelerated rapidly, widespread adoption across healthcare systems remains uneven.
This panel discussion will bring together leaders from diagnostics, clinical medicine, health systems, payer organizations, policy, and investment to examine what it takes for innovative early-detection diagnostics to gain traction in real-world healthcare environments across clinical, payer, and policy settings. Panelists will explore how emerging tools—including liquid biopsies, genomic screening, proteomics, digital biomarkers, and AI-enabled diagnostics—are reshaping personalized medicine and redefining prevention-oriented care.
As precision medicine reshapes healthcare, the U.S. Food and Drug Administration plays a critical role in translating scientific innovation into safe, effective, and accessible patient care. This session will explore how regulatory frameworks are evolving to keep pace with advances in genomics, biomarkers, and targeted therapies. Panelists will discuss accelerated approvals, real-world evidence, evolving standards for evaluating personalized treatments, and the policy decisions shaping patient access to innovation. The discussion will also examine how the FDA can continue to support cutting-edge science while maintaining the rigorous standards that have been the steadfast guidepost that underpins public trust and patient safety globally.
PART II
Personalized Medicine In Practice: Adoption, Access & Impact
SPEAKER | Lauren Silvis, J.D., Senior Vice President, External Affairs, Tempus
Precision medicine is transforming healthcare by enabling more targeted, individualized approaches to prevention, diagnosis, and treatment. Yet behind every genomic profile, biomarker test, or personalized therapy is a patient navigating uncertainty, complex decisions, and evolving care pathways. This panel brings together influencers across the continuum of research and care to explore how personalized medicine is experienced in the real world.
Panelists will discuss successful approaches to patient engagement that have helped to accelerate research, improve adoption of precision approaches, and shaped more effective policy and care delivery. There is much progress to be made, and this conversation will also focus on the gaps that remain, and how stakeholders can better partner
As precision medicine moves from innovation to broader clinical adoption, community health systems face growing questions and a different set of challenges around value, measurement, and sustainability. This session will explore how healthcare organizations can evaluate the clinical, operational, and economic impact of implementing personalized medicine at scale. Topics will include quality metrics, patient outcomes, return on investment, guiding care delivery improvements, and the evidence needed to support reimbursement and long-term adoption. The discussion will also examine the role of government and payer stakeholders in advancing coverage, access, and implementation strategies for precision medicine across U.S. healthcare systems and speak to case examples for guideline concordant biomarker testing versus adopting new testing modalities.
As precision medicine continues to advance, payers face growing challenges in determining how to provide timely access to innovative therapies and testing while ensuring clinical evidence, affordability, and appropriate utilization. This session will explore the payer perspective on coverage decisions related to biomarker testing, gene sequencing, prior authorization, step therapy, and targeted treatments.
Panelists will discuss what payers are doing to reduce unnecessary barriers to access, including modernizing coverage policies, streamlining utilization management, incorporating real-world evidence, and partnering across the healthcare ecosystem to support individualized care. Through real-world patient experiences, the conversation will also examine where gaps in coverage and administrative complexity continue to impact diagnosis, treatment decisions, and outcomes, and what policy and system-level changes may help improve equitable access to precision medicine.
Global personalized medicine initiatives are rapidly transforming R&D, healthcare delivery, and patient outcomes. As organizations across the personalized medicine ecosystem move from asking whether to collaborate to determining how to collaborate effectively, this session will examine the partnership models, affiliations, and strategic alliances that are enabling innovation at scale across regions and health systems worldwide.
Panelists will explore how governments, healthcare systems, academic institutions, industry leaders, and patient-focused organizations are structuring successful global collaborations to expand access, accelerate research, and advance implementation of personalized medicine. The discussion will highlight key strategic, operational, and governance considerations that shape effective international partnerships, along with practical lessons learned from real-world initiatives across diverse markets and healthcare environments.
By examining successful models from around the world, this session will provide insights into how well-designed collaborations can strengthen infrastructure, foster data sharing and innovation, improve equity and access, and accelerate the global impact of personalized medicine.
SPEAKER | Gina Ross Murdoch, MBA, President & CEO, Personalized Medicine Coalition